Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment, i.e., atopic dermatitis (AD), nodular prurigo, and asthma (4, 5). The gene discussed is IL4; the disease is asthma.